Cleerly Highlights Growing Interest in AI Cardiac Imaging at ACC26

According to a recent LinkedIn post from Cleerly, the company recently participated in the American College of Cardiology’s ACC26 meeting, where its team held discussions around advanced plaque analysis for coronary artery disease. The post indicates that Cleerly emphasized how its AI-driven imaging aims to provide a more comprehensive view of patients’ CAD to support treatment decisions.

The post also points to rising interest potentially linked to a new Category I CPT code and expanded insurance coverage for its technology. For investors, this suggests growing clinical and payer traction, which could support higher utilization rates, revenue visibility, and stronger positioning within the cardiac imaging and AI-enabled diagnostics market.